Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Sponsor: Dana-Farber Cancer Institute
Summary
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Official title: A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
23
Start Date
2014-09-29
Completion Date
2022-01-01
Last Updated
2026-11-05
Healthy Volunteers
No
Conditions
Interventions
BKM120
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Cisplatin
Cisplatin is a chemotherapy drug
Intensity-modulated radiotherapy (IMRT)
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Locations (1)
Dana-Farber Cancer Institute
Boston, Massachusetts, United States